Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

24. März 2015 15:04 ET | Quelle: Agios Pharmaceuticals, Inc.

Agios Pharmaceuticals Announces Orphan Drug Designation of AG-348 for Treatment of Pyruvate Kinase Deficiency

- PK deficiency is a severe and rare genetic disease with currently no approved or disease modifying treatments - CAMBRIDGE, Mass., March 24, 2015 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc....
20. Februar 2015 08:30 ET | Quelle: Agios Pharmaceuticals, Inc.

Agios Pharmaceuticals to Present at Cowen and Company 35th Annual Health Care Conference on Monday, March 2

CAMBRIDGE, Mass., Feb. 20, 2015 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq:AGIO), a leader in the fields of cancer metabolism and rare genetic disorders of metabolism, today announced the...
17. Februar 2015 07:30 ET | Quelle: Agios Pharmaceuticals, Inc.

Agios Pharmaceuticals Reports Fourth Quarter and Full Year 2014 Financial Results

CAMBRIDGE, Mass., Feb. 17, 2015 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq:AGIO), a leader in the fields of cancer metabolism and rare genetic disorders of metabolism, today reported...
10. Februar 2015 08:30 ET | Quelle: Agios Pharmaceuticals, Inc.

Agios Pharmaceuticals to Webcast Conference Call of Fourth Quarter and Full Year 2014 Financial Results on February 17, 2015

CAMBRIDGE, Mass., Feb. 10, 2015 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq:AGIO), a leader in the fields of cancer metabolism and rare genetic disorders of metabolism, today announced...
03. Februar 2015 08:30 ET | Quelle: Agios Pharmaceuticals, Inc.

Agios Pharmaceuticals to Present at the 2015 Leerink Global Healthcare Conference on Wednesday, February 11

CAMBRIDGE, Mass., Feb. 3, 2015 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq:AGIO), a leader in the fields of cancer metabolism and rare genetic disorders of metabolism, today announced the...
12. Januar 2015 16:05 ET | Quelle: Agios Pharmaceuticals, Inc.

Agios Announces that Celgene Has Agreed to Exercise its Option to License AG-120 under Global Strategic Collaboration

CAMBRIDGE, Mass., Jan. 12, 2015 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq:AGIO), a leader in the fields of cancer metabolism and rare genetic disorders of metabolism, today announced...
05. Januar 2015 16:05 ET | Quelle: Agios Pharmaceuticals, Inc.

Agios Pharmaceuticals to Present at the 33rd Annual J.P. Morgan Healthcare Conference on Monday, January 12

CAMBRIDGE, Mass., Jan. 5, 2015 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq:AGIO), a leader in the fields of cancer metabolism and rare genetic disorders of metabolism, today announced the...
16. Dezember 2014 16:05 ET | Quelle: Agios Pharmaceuticals, Inc.

Agios Pharmaceuticals Announces Closing of Public Offering and Full Exercise of Over-Allotment Option

CAMBRIDGE, Mass., Dec. 16, 2014 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq:AGIO) today announced the closing of its previously announced underwritten public offering of common stock,...
10. Dezember 2014 20:41 ET | Quelle: Agios Pharmaceuticals, Inc.

Agios Pharmaceuticals Announces Pricing of $220 Million Public Offering of Common Stock

CAMBRIDGE, Mass., Dec. 10, 2014 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq:AGIO) today announced that it has priced an underwritten public offering of 1,986,455 shares of common stock at...
09. Dezember 2014 16:22 ET | Quelle: Agios Pharmaceuticals, Inc.

Agios Pharmaceuticals Announces Proposed Offering of Common Stock

CAMBRIDGE, Mass., Dec. 9, 2014 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq:AGIO) today announced that it is offering to sell, subject to market and other conditions, up to $175 million of...

Vorherige Seite